Eledon Pharmaceuticals (NASDAQ:ELDN) Announces Earnings Results, Misses Estimates by $0.30 EPS

Eledon Pharmaceuticals (NASDAQ:ELDN) released its earnings results on Thursday. For the latest quarter, the company reported an earnings per share (EPS) of ($0.64), which fell short of analysts' expectations of ($0.34) by $0.30. In the same quarter last year, Eledon had reported an EPS of ($1.00).

Eledon Pharmaceuticals Stock Performance

On Friday, Eledon Pharmaceuticals shares increased by $0.03, reaching a trading price of $3.47. The trading volume for the day was 55,964 shares, while the average trading volume stands at 275,245 shares. Over the past year, the stock has seen a low of $1.52 and a high of $5.54. Currently, Eledon has a market capitalization of $207.35 million, with a price-to-earnings ratio of -1.74 and a beta value of 0.80. The stock’s 50-day moving average is $4.18, while the 200-day moving average is $3.85.

Analyst Upgrades and Downgrades

In a recent research report, Guggenheim began coverage of Eledon Pharmaceuticals on January 28th, granting the company a "buy" rating with a price target of $9.00.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that focuses on immunology. The firm is working on developing therapies that target the CD40 Ligand (CD40L, also known as CD154) pathway to protect transplanted organs, alleviate rejection, and treat diseases like amyotrophic lateral sclerosis (ALS).

Eledon, Earnings, Pharmaceuticals